Orchid Pharma Limited has made a regulatory disclosure under Regulation 30 of SEBI Listing Regulations regarding the implementation of a scheme of amalgamation. This intimation is in continuation of earlier communications dated July 10, 2026 and July 28, 2026.
Key Quantitative Figures
The company will issue 4,45,86,052 (4.45 crore) fully paid-up equity shares of ₹10 each to eligible shareholders of Dhanuka Laboratories Limited. The record date for determining eligible shareholders was July 23, 2026.
Capital Structure Impact
Post-allotment and after cancellation of cross-holding of Dhanuka Laboratories Limited, the paid-up share capital of Orchid Pharma Limited has become ₹59,88,52,000 (Rupees Fifty nine crore eighty eight lakh fifty two thousand only) divided into 5,98,85,200 (five crore ninety eight lakh eighty five thousand two hundred) equity shares of ₹10 each.
Listing and Trading Details
The newly allotted shares will be listed and traded on both BSE Limited and National Stock Exchange of India Limited. These shares shall rank pari-passu with the existing equity shares of the company.
Annexure-I Details
The annexure specifies that the securities issued are equity shares through allotment pursuant to scheme of amalgamation (not preferential issue, bonus issue, depository receipts, or debt securities). The total number of securities issued is 4,45,86,052 equity shares ranking pari passu to existing equity shares. All other categories (preferential issue, bonus issue, ADR/GDR/FCCB, debt securities) are marked as "NA" (not applicable).